Noze, a Montreal, Canada-based leader in breath-based diagnostics, secured a $5m equity investment from the Bill & Melinda Gates Foundation.
The funding follows two previous grants from the foundation, bringing its total contribution to $6.8m.
The company intends to use the funds for further development of its disease detection platform for deployment in low and middle-income countries.
Led by CEO Karim Aly, Noze is the global leader in digital odor perception. Featuring an advanced digital nose, Noze accurately detects and identifies odors in real-world settings with precision. Its handheld diagnostic breathalyzer, DiagNoze®, uses digital odor perception technology to detect disease biomarkers in the breath. The device will allow for real-time detection of serious illnesses such as cancers and infectious diseases, along with other clinical conditions, without requiring blood draws, lab equipment, or visits to healthcare facilities. DiagNoze is a low-cost, completely noninvasive, and fully portable device that can be used in any point-of-care, even a patient’s home.
FinSMEs
31/07/2024